Clinical trials: Primary Immunodeficiency Disorders (PIDs)
Humoral Primary Immunodeficiencies (PIDs), Secondary Form of Humoral Immunodeficiencies
Study of Populations at Risk of Developing Chronic Hepatitis Linked to Chronic Enteric Virus Infection in Patients With Primary Immunodeficiency and Secondary Humoral Deficiency
Dysimmune and specially hepatic immuno-pathological processes are frequent in patients with PIDs (primary immune deficiencies), particularly but not exclusively in patients with humoral defects.
- Conditions
- Humoral Primary Immunodeficiencies (PIDs), Secondary Form of Humoral Immunodeficiencies, Combined Immunodeficiency (CID), Severe Combined Immunodeficiency (SCID)
- Trial name
- EVAH (NCT06659588)
- Testing
- Plasma, urine and stool collection
- Where
- 3 sites in France
- Volunteers
- 200 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Primary Immunodeficiency Disorders (PIDs)
Leniolisib for Immune Dysregulation in PIDs
This study is an exploratory, non-randomized, open-label, within-patient dose escalation study. The primary objective is to assess safety and tolerability of leniolisib.
- Trial name
- NCT06549114
- Testing
- Leniolisib
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Pharming Technologies B.V.
PIDs Linked to PI3K
Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation
This is an open-label extension (OLE) study to extend treatment to patients with primary immunodeficiency (PID) disorders linked to phosphoinositide 3-kinase delta signaling who participated in a prior study of leniolisib, LE…
- Trial name
- NCT06990529
- Testing
- Leniolisib
- Where
- 5 sites in United States, Spain and 1 more
- Volunteers
- 12 people
- Sponsor
- Pharming Technologies B.V.